Anacetrapib: New Drug Could Dramatically Reduce Cholesterol

Merck has a potential blockbuster in anacetrapib, an experimental cholesterol drug that dramatically increases HDL, or “good” cholesterol even as it lowers LDL, also known as “bad” cholesterol.

But don’t hold your breath. Cardiologists, patients and investors will have to wait until at least 2015 to find out whether the drug protects the heart by reducing heart attacks and other cardiovascular problems, Merck said.

READ MORE